/PRNewswire/ Medcura, Inc., a commercial-stage medical device company, today announced it has raised $7.4 million in private equity to support its growing.
Gaining depth on gain of function
Yesterday I posted “The fallacious Fauci strikes again.” My comments elicited a message from Michael S. Rogers, Assistant Professor of Surgery at Harvard Medical School and Research Associate in the Vascular Biology Program at Boston Children’s Hospital. I thought some readers might find it of interest. With his permission I am posting his message below the break.
The question of whether the 2017 PLoS Pathogens paper contains gain of function experiments has recently been in the news. Since I have significant experience (30 years) in the recombinant DNA techniques in question, I thought I might lay out what was done in the experiments and let you decide.
Dr. Samuel Lin Continues Partnership With Haute Beauty Network
Share Article
Nose Expert from Boston, Dr. Samuel Lin, continues partnership with Haute Beauty Network, now in his third year.
Dr. Lin is the editor of several medical textbooks including Aesthetic Atlas of the Head and Neck, Atlas of Body Contouring, and Plastic and Reconstructive Surgery Pearls of Wisdom and Pearls of Wisdom Second and Third Editions. BOSTON (PRWEB) January 20, 2021 Dr. Samuel Lin is a double board-certified Plastic Surgeon and Associate Professor of Surgery at Harvard Medical School who practices in Boston, Massachusetts. Dr. Lin received his Bachelor’s degree in Biomedical Engineering at Northwestern University and was enrolled in the Honors Program for Medical Education at Northwestern University, Feinberg School of Medicine, Chicago, Illinois. He then completed a five-year residency in Otolaryngology-Head and Neck Surgery fol
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research .
Tonix Pharmaceuticals Holding Corp.January 5, 2021 GMT
Expands Ongoing Research Collaboration Between Tonix and MGH Studying TNX-1500 in Heart Transplantation
TNX-1500 May Hold Potential in Treating Autoimmune Diseases Including Systemic Lupus Erythematosus, Rheumatoid Arthritis and Multiple Sclerosis
CHATHAM, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the signing of a second research collaboration agreement with Massachusetts General Hospital (MGH), a teaching hospital of Harvard Medical School, to develop TNX-1500, a humanized monoclonal antibody (mAb) that targets the CD40-ligand (also known as CD154, T-BAM or 5c8 antigen1) for the prevention and treatment of organ trans